Source:http://linkedlifedata.com/resource/pubmed/id/17015749
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0162638,
umls-concept:C0178539,
umls-concept:C0279023,
umls-concept:C0301625,
umls-concept:C0664750,
umls-concept:C0754623,
umls-concept:C1269955,
umls-concept:C1522538,
umls-concept:C1879547,
umls-concept:C1999216,
umls-concept:C2699153
|
pubmed:issue |
8
|
pubmed:dateCreated |
2006-10-3
|
pubmed:abstractText |
Deguelin, a constituent of the bark of the African plant Mundulea sericea (Leguminosae), exhibits antiproliferative and anticarcinogenic activities through a mechanism that is not well understood. Because various steps in carcinogenesis are regulated by NF-kappaB, we postulated that the activity of deguelin is mediated through this transcription factor. We found that deguelin suppressed NF-kappaB activation induced by carcinogens, tumor promoters, growth factors, and inflammatory stimuli. This suppression was not cell-type specific, because NF-kappaB activation was suppressed in both lymphoid and epithelial cells. Moreover, constitutive NF-kappaB activation was also blocked by deguelin. The suppression of TNF-induced NF-kappaB activation by deguelin occurred through the inhibition of the activation of IkappaBalpha kinase, leading to sequential suppression of IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 phosphorylation, p65 nuclear translocation, and NF-kappaB-dependent reporter gene expression. Deguelin also suppressed the NF-kappaB reporter activity induced by TNFR1, TNFR-associated death domain, TNFR-associated factor 2, and IkappaBalpha kinase, but not that induced by p65. The inhibition of NF-kappaB activation thereby led to the down-regulation of gene products involved in cell survival, proliferation, and invasion. Suppression of these gene products by deguelin enhanced the apoptosis induced by TNF and chemotherapeutic agents and suppressed TNF-induced cellular invasion. Our results demonstrate that deguelin inhibits the NF-kappaB activation pathway, which may explain its role in the suppression of carcinogenesis and cellular proliferation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/I-kappa B Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/NF-kappa B,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/Rotenone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/deguelin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
177
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5612-22
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17015749-Antineoplastic Agents,
pubmed-meshheading:17015749-Apoptosis,
pubmed-meshheading:17015749-Cell Proliferation,
pubmed-meshheading:17015749-Cells, Cultured,
pubmed-meshheading:17015749-Drug Interactions,
pubmed-meshheading:17015749-Epithelial Cells,
pubmed-meshheading:17015749-Gene Expression Regulation,
pubmed-meshheading:17015749-Humans,
pubmed-meshheading:17015749-I-kappa B Kinase,
pubmed-meshheading:17015749-Lymphocytes,
pubmed-meshheading:17015749-NF-kappa B,
pubmed-meshheading:17015749-Neoplasm Invasiveness,
pubmed-meshheading:17015749-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:17015749-Rotenone,
pubmed-meshheading:17015749-Tumor Necrosis Factor-alpha
|
pubmed:year |
2006
|
pubmed:articleTitle |
Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion.
|
pubmed:affiliation |
Department of Experimental Therapeutics, Cytokine Research Laboratory, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|